“Global Rabies Diagnostics Market is anticipated to surpass USD 1.8 billion by 2020”, says Visiongain

07 November 2019
Pharma

Visiongain has launched a new pharma report Rabies Diagnostics Market Report ” Prospects by Diagnostic Method (Fluorescent Antibody Test (FAT), Immunohistochemical Test, Amplification Methods, Histologic Examination, Serology Tests), Technology (Chromatography Techniques, ELISA/Immunohistochemistry, PCR, Other Technologies) and Geography.

Global rabies diagnostics market is projected to grow on account of a high prevalence of rabies cases coupled with a growing number of dog bites, the presence of research funding programs, and supportive government initiatives among other growth contributing factors. The global market is projected to grow at a lucrative CAGR of ~4% over the forecast period 2020-2030 and anticipated to surpass USD 1.8 billion by 2020.

In the coming years, the global market for rabies diagnostics is expected to expand rapidly. It is expected that factors such as a new set of guidelines, new products and an increase in the number of rabies-infected people and animals will boost the growth of the rabies diagnostics market. 

Some of the leading assays are Quicking Pet Rapid kit by Quicking Biotech, Bionote's Anigen Rapid Rabies Ag kit, Ubio's quickVET Rabies Antigen Rapid check, Creative Diagnostic Rapid Rabies Ag kit, Green Spring's Rabies Virus Ag Rapid test, and BioGen Technologies ' vet-o-test Rabies Ag. In April 2018, a new set of guidelines and recommendations was released by the World Health Organization (WHO), addressing key elements such as exclusion, control, and prevention of rabies. It is expected that the new set of guidelines will provide guidance and regulations to eradicate rabies, especially in developing countries dealing with an increase in the number of rabies cases. Some of the key changes in the guidance for eliminating rabies are the focus on difficult monitoring techniques, easy testing kits for rabies, and immunization recommendations.

Several international healthcare organizations are working with healthcare organizations to develop and market new detection assays to drive efforts aimed at fighting the disease. For instance, the World Health Organization is involved in promoting research efforts to control rabies across the globe in partnership with other healthcare organizations, such as provincial health authorities.

Due to the higher penetration of products based on ELISA / immunohistochemistry protocols, ELISA / Immunohistochemistry represented the largest market share. This technology is based on numerous test methods including RREID, FAT, dRIT, IRIT, and RIDT. Methods focused on immunohistochemistry offer significant benefits that have led to the high adoption of this technology, which in turn is expected to fuel segment growth in the coming years.

The outbreak of rabies occurs in more than 150 countries, but its dominance is majorly seen in Asian and African countries. According to the WHO, in Asia, 31,000 human deaths occur every year due to rabies. Recent data and figures have demonstrated the need for several control systems that will fuel market growth in the years ahead.

However, due to the widespread use of diagnostic tests in the country, the U.S. market is expected to grow significantly throughout the forecast period. The Centers for Disease Control and Prevention (CDC) estimates that in the United States more than 125,000 animals are vaccinated annually for rabies.

Some of the major players operating in this industry are Abbexa Ltd., Aviva Systems Biology Corporation, Bio-Rad Laboratories, Inc., BioNote, Inc., Creative Diagnostics, Demeditec Diagnostics GmbH, Express Biotech International Inc., Merck KGaA, MyBioSource.com, Norgen Biotek Corp., ANTECH Diagnostics, Geniron Biolabs (P) Ltd. among other prominent players.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020

Read

Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.

26 November 2020

Read

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

Read

Visiongain Publishes Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031

Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth

24 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever